Platform designs and multi-stage designs do have the potential to increase the efficiency of identifying effective treatments, if not the efficiency of any particular 2-arm comparison, by utilizing a single control group and avoiding the time and administrative burden of opening multiple trials. At a time when new agents are rapidly being developed and coming out of phase 1, platform trials will indeed be an efficient way to prioritize agents for entry into confirmatory efficacy trials.Read more
About this blog
CRIT is no longer adding posts or updating the CRITical Thinking blog.
CRITical Thinking is a blog written by staff, directors, and friends of the Collaboration for Research Integrity and Transparency (CRIT), a joint program of Yale Law School, Yale School of Public Health, and Yale School of Medicine. CRIT's mission is to promote health by improving the integrity and transparency of biomedical and clinical research.
This blog is published by and reflects the personal views of the individual authors, in their individual capacities. It does not purport to represent Yale University's institutional views, if any. No representation is made about the accuracy of the information, which solely constitutes the authors’ personal views on issues discussed. The information contained in this blog is provided only as general information and personal opinions, and blog topics may be updated after being initially posted.